366
Participants
Start Date
September 20, 2017
Primary Completion Date
December 15, 2017
Study Completion Date
November 9, 2018
3.75 ug Panblok H7
0.5 mL recombinant Panblok H7 influenza vaccine antigen 15 ug/mL.
7.5 ug Panblok H7
Mix 0.5 mL recombinant Panblok H7 influenza vaccine antigen 30 ug/mL.
15 ug Panblok H7
Mix 0.5 mL recombinant Panblok H7 influenza vaccine antigen 60 ug/mL.
MF59
0.5 mL MF59 (39 mg squalene/mL ) adjuvant.
AS03
0.5 mL AS03 (42.4 mg squalene/mL ) adjuvant.
Rochester Clinical Research, Inc, Rochester
Central Kentucky Research Associates, Inc., Lexington
Johnson County Clin-Trials, Lenexa
Heartland Research Associates, LLC, Wichita
Rho, Inc.
INDUSTRY
Biomedical Advanced Research and Development Authority
FED